Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Controlled Human Infection Model in Malawi
NCT06178666Not yet recruiting
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of bcg vaccine in Tuberculosis (TB) (3 arms), sponsored by Liverpool School of Tropical Medicine. Primary endpoint: Culture and PCR ascertainment of BCG load at 14 days. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
bcg vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06178666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178666.